Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_775_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
46 Мб
Скачать
424
M. Abdel-Wahab and A. Shehta
Staging laparoscopy can be useful in ruling out small peritoneal implants or distant LN disease. When associated with intraoperative ultrasound, it can evaluate the extent of intrahepatic disease, vascular invasion and reveal intraparen­chymal metastasis. Therefore, it has a potential role in detect­ing unresectable disease and avoiding unessential laparotomy, which has been reported to happen in 25–36% of patients [11, 24]. Staging laparoscopy is essentially important in high-risk patients especially those patients with suspected multifocal ICC, suspected peritoneal implants or major vas­cular invasion, and those with high preoperative tumor mark­ers. The routine use of laparoscopic ultrasound in these cases is therefore advocated.
Also, it is important to carefully evaluate the condition of the hepatic parenchyma, especially the presence of chronic liver disease or cirrhosis which could limit or contraindicate the surgical resection [25].

57.11 Surgical Resection Procedure

Surgical therapy for ICC is based on the surgical principles applied to resection for any hepatic malignancy. Anatomical liver resection with wide margins is generally recommended for ICC if adequate functional liver remnant with adequate venous and biliary drainage remains.
ICC usually develops on a background of non-cirrhotic liver; thus, extended resections can be safely performed (Fig. 57.1b). Advanced stages of ICC can be treated by extended hepatic resection with extension of the resection to the extrahepatic biliary tree, vascular hilar structures, hepatic veins, inferior vena cava, and diaphragm [11, 26]. Studies addressing surgical resection for ICC are summarized in Table57.1.
The intraductal growth type of ICC is associated with intraductal growth with intraductal tumor thrombus. In these patients, the biliary duct margin should be evaluated by intraoperative frozen section after major hepatic resec­tion. If neoplastic invasion of the bile duct margin is found, extended resection of the extrahepatic biliary tree should be performed [40].
The mass forming type of ICC is associated with high incidence of satellite nodules. It is essential to perform intra­operative ultrasonography in order to identify the presence of metastatic nodules and a radical transection plane [26].
Vascular invasion may be found in about 27%–85% of patients with ICC [46]. Previous studies had shown that the survival outcomes of patients who underwent surgical resec­tion are better than those who did not underwent surgical resection [47]. Vascular resection in combination with hepa­tectomy increases not only the probability to achieve nega­tive surgical margins, but also the incidence of postoperative
Table 57.1 Short- and long-term outcomes of surgical resection for intrahepatic cholangiocarcinoma
Study Year N Morbidity (%) Cherqui etal. [12] 1995 14 28 7 27 100 Pichlmayr etal. [27] 1995 32 10.5 12.8 Casavilla etal. [28] 1997 34 60 37 31 Madariaga etal. [29] 1998 34 32 14 19 67 40 25 Chu etal. [30] 1999 39 41.7 16.7 12.2 57.3 23.9 15.9 Weber etal. [31] 2001 33 37 31 Kawarada etal. [32] 2002 37 21.6 0 31.5 54.1 34 23.9 Ohtsuka etal. [33] 2002 48 50 8 62 38 23 Lang etal. [24] 2005 16 52 6 46 94 82 Nakagawa etal. [34] 2005 44 69 5.7 22 66 26 De Oliveira etal. [35] 2007 34 35 4 28 63 Endo etal. [2] 2008 82 36 Guglielmi etal. [36] 2009 62 32 3.8 41 26 Lang etal. [37] 2009 83 58 7 26 71 21 Nathan etal. [38] 2009 598 21 18 Shen etal. [39] 2009 429 12 51 17 De Jong etal. [40] 2011 449 27 78 31 Farges etal. [41] 2011 212 28 77 28 Saiura etal. [42] 2011 44 35 0 41 87 56 43 Sriputtha etal. [43] 2013 73 12.4 52.1 21.7 11.2 Luo etal. [44] 2014 1333 11.5 0.6 30 79.1 42.6 28.7 Ali etal. [45] 2015 150 44 84 43 Tabrizian etal. [3] 2015 82 16 60 24 16
N, patient number; Ys, years
30days mortality (%)
Median survival (month)
Survival (%) 1 Y 3 Ys 5 Ys
57 Surgical Management ofIntrahepatic Cholangiocarcinoma
425
major complications. Therefore, liver resection in combina­tion with inferior vena cava and portal vein partial resection plus reconstruction or hepatic artery resection may be con­sidered in adequately assessed cases to achieve a R0 resec­tion. Therefore, vascular invasion does not represent an absolute contraindication for surgical resection.
Patients with untreated IHCC have a median survival of less than 12 months. Resection with positive margins or residual macroscopic disease is associated with median sur­vival of 1.8–3 months, indicating that a cytoreductive approach is ineffective at prolonging survival. In contrast, 5-year survival rates after complete resection range between 13% and 43% [26].
57.12 Status ofLymphadenectomy
Although the importance of achieving an R0 resection is clear, the role of routine lymph node dissection is debated. The presence and extent of nodal metastatic disease are important prognostic factors. Current National Comprehensive Cancer Network (NCCN, 2012) guidelines suggest that regional lymphadenectomy should be consid­ered in patients to provide staging information, but that resection should be carefully considered in patients with bulky nodal disease in the porta hepatis [48].
With respect to staging, uniform agreement is lacking on the optimal number of nodes harvested per patient. Usually, three or less are harvested [40], although up to seven nodes are suggested for patients with hilar cholangiocarcinoma [49]. This has led Guglielmi and associates to suggest that the lymph node ratio (LNR) is an important prognostic fac­tor, with an LNR of greater than 0.25 associated with worse survival (19months, compared to 43 months with LNR of zero) [36].
Currently, there is no clear therapeutic benet attributable to routine nodal dissection accompanying hepatectomy for ICC. Thorough assessment of all intraabdominal nodal basins should be undertaken before hepatic resection, and sampling of suspicious nodes is indicated to stage disease accurately, which may direct postoperative treatment.
Major lymphatic spread of ICC follows three routes. First, through the hepatoduodenal ligament. Second, through the paracardial, lesser curvature, and left gastric artery. Third, through the inferior phrenic artery to the para-aortic group. Consequently, the extent of radical lymphadenectomy should include the hepatoduodenal ligament with hepatic artery, para-aortic, retro-pancreatic, and left gastric lymph nodes [36, 50].
57.13 Results ofSurgery
57.13.1 Morbidity andMortality
Surgical resection for ICC is a complex surgical procedure. Despite the improvement of surgical techniques and periop­erative patients’ care, extended liver resection still entails signicant perioperative morbidities and mortality.
The rate of postoperative complications following surgi­cal resection for ICC is variable between 11.5% and 58%, as shown in Table 57.1. The incidence is comparable to that reported following liver resection in non-cirrhotic patients. Posthepatectomy liver failure is less frequent among this group of patients when compared to liver resection for hepa­tocellular carcinoma. Other complications include bile leak­age, abdominal infection, pulmonary embolism, and respiratory complications [24, 43].
The postoperative complications rate is also related to the extent of surgical resection. Lang etal. reported higher inci­dence among ICC patients who underwent extended hepatic resection with vascular and hilar resection (56%), when compared to simple liver resections (45%) [24].
On the other hand, postoperative mortality following sur­gical resection for ICC is variable between 0% and 16.7%, as shown in Table57.1. The most common causes of postopera­tive mortality are liver failure, septic shock, and multiple organ dysfunction [40].

57.13.2 Long-Term Outcomes

The prognosis after surgical resection of ICC is still unsatis­factory. The s-years overall survival rate after surgical resec­tion of ICC varies from 0% to 43% in the most recent series as shown in Table57.1. The main reasons for these outcomes are the late diagnosis due to lack of specic symptoms or risk factors for screening, and spread of ICC through the intrahe­patic and lymphatic metastasis [2]. A better survival rate as high as 63% could be achieved in ICC patients with negative margins (R0 resections) and negative lymph node involve­ment [31, 51].
Several prognostic factors for long-term survival after liver resection for ICC had been identied. A propensity score matching analysis showed that the use of nomograms is a good way to predict survival after resection. Wang etal. developed a nomogram for ICC, including tumor (T) and nodal (N) classications, tumor size, the number of tumor nodules, preoperative level of serum tumor markers, and presence of vascular invasion [52].
426
M. Abdel-Wahab and A. Shehta

57.14 Recurrence

Recurrence after R0 resection is frequent ranging between 38% and 82%. Most of recurrences occur early postoperative and most commonly in the rst two years after surgical resection [3, 53]. Local recurrence is the most common recurrence pattern after radical surgical resection [54], although other patterns such as lymph nodes, abdominal wall, and extrahepatic distant recurrences were also observed [55]. A study utilizing an international database investigated 563 patients underwent curative-intent resection for ICC with a median follow-up of 19months and found that the most common recurrence site was intrahepatic only (59.8%), extrahepatic only (14.5%), or both intra- and extrahepatic (25.7%) [56].
Management of recurrence has not been established in lit­erature. Most of these patients receive only palliative ther­apy. Salvage surgery for intrahepatic recurrence or metastasectomy is usually not indicated, because it is des­tined to be followed by further rapid recurrences [31, 57].

57.14.1 Liver Transplantation

The role of transplantation in ICC will continue to be limited by the lack of a truly effective adjuvant systemic treatment regimen. This is in contrast to the emerging protocol of neo­adjuvant chemoradiation before transplantation for hilar cholangiocarcinoma [58].
The rst signicant report regarding liver transplantation for ICC is that of Pichlmayr etal. in 1995. They reported a median survival of 5months in 18 patients treated with liver transplantation, with a 1-year survival rate of 13.9% [59]. Several studies conrmed these ndings afterwards [60, 61]. Cherqui et al. reported two long-term survivors and con­cluded that a patient with an intrahepatic tumor with no extrahepatic spread that cannot be resected for anatomic reasons may be a candidate for liver transplantation [12]. More recent experience has resulted in improved survival, with disease-free survival at 5 and 10years of 27% and 23%, respectively, reported in 23 patients with IHCC treated with orthotopic liver transplantation [62]. However, liver trans­plantation remains a controversial issue due to the controver­sial indications and low cost-effectiveness which limit its use in treatment of ICC.

References

1. Wang K, Zhang H, Xia Y, etal. Surgical options for intrahepatic
cholangiocarcinoma. Hepatobil Surg Nutr. 2017;6(2):79.
2. Endo I, Gonen M, Yopp AC, etal. Intrahepatic cholangiocarcinoma:
rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248:84–96.
3. Tabrizian P, Jibara G, Hechtman JF, et al. Outcomes following resection of intrahepatic cholangiocarcinoma. HPB (Oxford). 2015;17:344–51.
4. Brown KM, Parmar AD, Geller DA, etal. Intrahepatic cholangio­carcinoma. Surg Oncol Clin N Am. 2014;23:231–46.
5. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317–23.
6. Alvaro D.Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.
7. Cheon YK, Cho YD, Moon JH, etal. Diagnostic utility of inter­leukin- 6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol. 2007;102:2164–2170.
8. Slattery JM, Sahani DV. What is the current state-of-the-art imag­ing for detection and staging of cholangiocarcinoma? Oncologist. 2006;11:913–22.
9. Asayama Y, Yoshimitsu K, Irie H, etal. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology. 2006;238:150–5.
10. Ringe KI, Wacker F. Radiological diagnosis in cholangiocarci­noma: application of computed tomography, magnetic resonance imaging, and positron emission tomography. Best Pract Res Clin Gastroenterol. 2015;29:253–65.
11. Weber SM, Ribero D, O'Reilly EM, et al. Intrahepatic chol­angiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669–80.
12. Cherqui D, Tantawi B, Alon R, et al. Intrahepatic cholangiocar­cinoma. Results of aggressive surgical management. Arch Surg. 1995;130(10):1073–8.
13. Harrison LE, Fong Y, Klimstra DS, et al. Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma. Br J Surg. 1998;85(5):1068–70.
14. Waisberg DR, Pinheiro RS, Nacif LS, etal. Resection for intrahe­patic cholangiocellular cancer: new advances. Transl Gastroenterol Hepatol. 2018;3(60).
15. Thirunavukarasu P, Aloia TA. Preoperative assessment and optimization of the future liver remnant. Surg Clin North Am. 2016;96:197–205.
16. Nagino M, Kamiya J, Nishio H, etal. Two hundred forty consecu­tive portal vein embolizations before extended hepatectomy for bil­iary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.
17. Sulpice L, Rayar M, Boucher E, etal. Intrahepatic cholangiocarci­noma: impact of genetic hemochromatosis on outcome and overall survival after surgical resection. J Surg Res. 2013;180:56–61.
18. Shindoh J, Vauthey JN, Zimmitti G, et al. Analysis of the ef­cacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, includ­ing a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg. 2013;217:126–33.
19. Tanaka K, Matsuo K, Murakami T, etal. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): short­term outcome, functional changes in the future liver remnant, and tumor growth activity. Eur J Surg Oncol. 2015;41:506–12.
20. López-López V, Robles-Campos R, Brusadin R, etal. Tourniquet­ALPPS is a promising treatment for very large hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget. 2018;9:28267–80.
21. Aloia TA. Associating liver partition and portal vein ligation for staged hepatectomy: portal vein embolization should remain the gold standard. JAMA Surg. 2015;150:927–8.
22. Squires MH, Cloyd JM, Dillhoff M, et al. Challenges of surgi­cal management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2018;12:671–81.
23. Baron TH, Harewood GC, Rumalla A, etal. A prospective compari­son of digital image analysis and routine cytology for the identi-
57 Surgical Management ofIntrahepatic Cholangiocarcinoma
427
cation of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol. 2004;2:214–9.
24. Lang H, Sotiropoulos GC, Fruhauf NR.Extended hepatectomy for intrahepatic cholangiocarcinoma in 50 patients over a 5 year period. Ann Surg. 2005;241(1):134–43.
25. Isaji S, Kawarada Y, Taoka H, et al. Clinicopathological features and outcomes of hepatic resection for intrahepatic cholangiocarci­noma Japan. J Hepato-Biliary-Pancreat Surg. 1999;6(2):108–16.
26. Mavros MN, Economopoulos KP, Alexiou VG, etal. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: sys­tematic review and meta-analysis. JAMA Surg. 2014;149:565–74.
27. Pichlmayr R, Weimann A, Klempnauer J, etal. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg. 1996;224(5):628.
28. Casavilla FA, Marsh JW, Iwatsuki S, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg. 1997;185(5):429–36.
29. Madariaga JR, Iwatsuki S, Todo S, etal. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg. 1998;227(1):70.
30. Chu KM, Fan ST.Intrahepatic cholangiocarcinoma in Hong Kong. J Hepato-Biliary-Pancreat Surg. 1999;6(2):149–53.
31. Weber SM, Jarnagin WR, Klimstra D, etal. Intrahepatic cholan­giocarcinoma: resectability, recurrence pattern and outcomes. J Am Coll Surg. 2001;193:384–91.
32. Kawarada Y, Yamagiwa K, Das BC.Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg. 2002;183(6):679–85.
33. Ohtsuka MH, Ito H, Kimura F, etal. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological fac­tors inuencing survival. Br J Surg. 2002;89(12):1525–31.
34. Nakagawa T, Kamiyama T, Kurauchi N, et al. Number of lymph node metastases is a signicant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg. 2005;29(6):728–33.
35. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755.
36. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg. 2009;33(6):1247–54.
37. Lang H, Sotiropoulos GC, Sgourakis G, etal. Operations for intra­hepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg. 2009;208(2):218–28.
38. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging sys­tem for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22.
39. Shen WF, Zhong W, Xu F, etal. Clinicopathological and prognos­tic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol: WJG. 2009;15(47):5976.
40. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.
41. Farges O, Fuks D, Le Treut YP, etal. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resect­able intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–7.
42. Saiura A, Yamamoto J, Kokudo N, etal. Intrahepatic cholangiocar­cinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg. 2011;201(2):203–8.
43. Sriputtha S, Khuntikeo N, Promthet S, Kamsaard S.Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pac J Cancer Prev. 2013;14(2):1107–10.
44. Luo X, Yuan L, Wang Y, et al. Survival outcomes and prognos­tic factors of surgical therapy for all potentially resectable intra­hepatic cholangiocarcinoma: a large single-center cohort study. J Gastrointest Surg. 2014;18(3):562–72.
45. Ali SM, Clark CJ, Mounajjed T, etal. Model to predict survival after surgical resection of intrahepatic cholangiocarcinoma: The Mayo Clinic experience. HPB. 2015;17(3):244–50.
46. Weinbren K, Mutum SS.Pathological aspects of cholangiocarci­noma. J Pathol. 1983;139(2):217–38.
47. Inoue K, Makuuchi M, Takayama T, etal. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127(5):498–505.
48. National Comprehensive Cancer Network (NCCN) guidelines, V 2,
2012. http://www.nccn.org.
49. Ito K, Ito H, Gonen M, Allen PJ, etal. Adequate lymph node assess­ment for extrahepatic bile duct cancer: do the data support the current AJCC recommendations?. J Clin Oncol. 2009;27(15_suppl):4576.
50. Tsuji T, Hiraoka T, Kanemitsu K, etal. Lymphatic spreading pattern of intrahepatic cholangiocarcinoma. Surgery. 2001;129(4):401–7.
51. Paik KY, Jung JC, Heo JS, etal. What prognostic factors are impor­tant for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol. 2008;23:766–70.
52. Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.
53. Huang JL, Biehl TR, Lee FT, et al. Outcomes after resection of cholangiocellular carcinoma. Am J Surg. 2004;187(5):612–7.
54. Hasegawa S, Ikai I, Fujii H, etal. Surgical resection of hilar chol­angiocarcinoma: analysis of survival and postoperative complica­tions. World J Surg. 2007;31:1256–63.
55. Zhu AX, Knox JJ.Adjuvant therapy for intrahepatic cholangiocar­cinoma: the debate continues. Oncologist. 2012;17:1504–7.
56. Spolverato G, Kim Y, Alexandrescu S, etal. Management and out­comes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23:235–43.
57. Chu KM, Fan ST.Intrahepatic cholangiocarcinoma in Hong Kong. J Hepato-Biliary-Pancreat Surg. 1999;6(2):149–53.
58. Fu B, Zhang T, Li H, etal. The role of liver transplantation for intra­hepatic cholangiocarcinoma: a single-center experience. Eur Surg Res. 2011;47:218–21.
59. Pichlmayl R, Lamesch P, Weimann A, etal. Surgical treatment of cholangiocellular carcinoma. World J Surg. 1995;19(1):83–8.
60. Ismail T, Angrisani L, Gunson BK, et al. Primary hepatic malig­nancy: the role of liver transplantation. Br J Surg. 1990;77(9):983–7.
61. O'Grady JG, Polson RJ, Rolles KE, etal. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988;207(4):373.
62. Robles R, Figueras J, Turrión VS, Margarit C, Moya A, Varo E, Calleja J, Valdivieso A, Valdecasas JC, López P, Gómez M.Spanish experience in liver transplantation for hilar and peripheral cholan­giocarcinoma. Ann Surg. 2004;239(2):265.
Hepatopancreatoduodenectomy (HPD) forBiliary Tract Cancers
TomokiEbata, TakashiMizuno, andShunsukeOnoe
58
Abstract
Biliary tract cancers exhibit various modes of local exten­sion, and some can only be resected by hepatopancreato­duodenectomy (HPD), which is dened as the resection of the whole extrahepatic biliary system with the adjacent liver and pancreatoduodenum. Early experiences with HPD were frequently associated with liver failure and subsequent mortality. However, with improvements in surgical techniques and perioperative patient care, the mortality rate after HPD has gradually reduced. Recent studies on HPD, although limited, have demonstrated a favorable survival in cholangiocarcinoma; whereas, con­troversial benet in gallbladder cancer because of the extremely poor survival. HPD is a standard approach for laterally-spreading cholangiocarcinoma that is otherwise unresectable.

58.1 Introduction

Biliary tract cancers (cholangiocarcinomas and gallbladder cancer) often exhibit an extensive ductal spread invading from the hepatic hilus to the lower bile duct, a bulky tumor mass invading the liver, pancreas, and duodenum, and an evi­dent nodal metastasis around the pancreatic head [1, 2]. Such extensive tumor spread represents a difcult local aggres­siveness because typical resection procedures, including hepatectomy or pancreatoduodenectomy (PD), cannot offer R0 resection. However, as only a complete resection poten­tially provides an improved long-term survival in biliary tract cancers [36], hepatectomy combined with pancreato­duodenectomy (i.e., hepatopancreatoduodenectomy [HPD]) can be theoretically considered a denitive surgery for
advanced biliary tract cancers. Even today, however, HPD for biliary cancer remains challenging and controversial because of rarity, very high-risk nature, and uncertain sur­vival benet.
58.1.1 Terminology Associated withHPD
HPD is a multivisceral resection that is dened as resection of the extrahepatic bile duct, the liver, the pancreatic head, and the duodenum (Figs.58.1 and 58.2). HPD is anatomi­cally characterized as complete removal of the entire extra­hepatic biliary system denoting the duct from the ampulla of Vater up to the hilar bile duct and the gallbladder, thereby suiting resection for biliary tract cancer (Fig. 58.3). Therefore, most HPDs include a hemihepatectomy or more extended hepatectomy. Occasionally, hepatectomy with pan­creatoduodenectomy or hepatectomy with pancreatectomy has been used as a synonym for HPD [7, 8]. For instance, PD and simultaneous partial liver resection is performed for pan­creatic endocrine tumor with hepatic metastasis [913] or for gallbladder cancer with peripancreatic node involvement [8,
14, 15]. The authors emphasize that this procedure is not
labeled as HPD (even if the right hepatectomy is combined) because the hilar bile duct remains in situ, which does not meet the above requirement of extirpation of the whole extrahepatic biliary system (Fig.58.4). Again, genuine HPD attempts to remove the entire extrahepatic biliary system with the adjacent liver and the pancreatoduodenum, repre­senting the most challenging procedure in the hepatobiliary eld.

58.1.2 Surgical Techniques

T. Ebata (*) · T. Mizuno · S. Onoe Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan e-mail: tomoki@med.nagoya-u.ac.jp
© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022 M. Makuuchi et al. (eds.), The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases,
https://doi.org/10.1007/978-981-19-0063-1_58
HPD has several variations in terms of types of hepatectomy and pancreatoduodenectomy. Here, we describe right hemi­hepatectomy with subtotal stomach-preserving PD as a com­mon example of HPD.Laparotomy is performed by a right
429
430
IVC
Stump of RPV
Fig. 58.1 Intraoperative photo of hepatopancreatoduodenectomy.
Right hemihepatectomy, caudate lobectomy, and pancreatoduodenec­tomy were performed for diffusely inltrating cholangiocarcinoma. Regional lymphadenectomies in the hepatoduodenal ligament (scissors indicate) and around the superior mesenteric artery (arrow) were com­pleted. The proximal bile duct was transected at the right side of the left portal vein (arrow head). IVC, inferior vena cava; RPV, right portal vein
Right liver
Gallbladder
Duodenum
Fig. 58.2 Typical resected specimen after hepatopancreatoduodenec-
tomy. The right liver, caudate lobe, extrahepatic biliary tree, duodeno­pancreas were removed en bloc
Left liver
Pancreas
Caudate lobe
Pancreatic head
Jejunum
T. Ebata et al.
subcostal incision with the midline upward extension. When peritoneal seeding, hepatic metastasis, or periaortic node metastasis (M1 disease) is conrmed by gross inspection or by frozen section histologic examination, HPD is absolutely contraindicated.
HPD is basically performed using the following steps. First, the common, proper, or left hepatic arteries, which feed the future liver remnant, are carefully dissected and pre­served. The left hepatic artery is further dissected toward the liver entry. When these major arteries cannot be isolated, the tumor is considered far-advanced local disease beyond the scope of resection. Otherwise, the right hepatic artery and the gastroduodenal artery are ligated and divided. The stom­ach is divided approximately 2cm proximal from the pylo­rus, and the superior mesenteric vein is exposed above and below the pancreatic neck.
Second, the jejunum is divided approximately 10–20cm distal from the ligament of Treitz. For lymphadenectomy along the superior mesenteric artery, the mesentery of the jejunum was resected along the second jejunal artery keep­ing in situ. The resection line is set upward along the left side of superior mesenteric artery; the root of the rst jejunal artery and infrapancreatoduodenal artery is divided. The upper jejunum and the fourth part of the duodenum are passed posterior to the superior mesenteric vessels toward the right side of the operative eld. The pancreatic nerve plexus intervening between the uncinate process and the superior mesenteric artery (i.e., the retroperitoneal soft tissue margin) is divided step-by-step along the right lateral border of the superior mesenteric artery. Tiny anonymous arteries are carefully divided. Then, the pancreas neck is sharply divided with a surgical knife, and a drainage tube is intro­duced into the main pancreatic duct after hemostasis. The remaining retropancreatic tissue and the posterior suprapancreatic duodenal vein are divided. The phase of pancreatoduodenectomy is completed.
Third, the lymph node clearance of the hepatoduodenal ligament is continued in the upward direction. The right por­tal vein is divided with vascular clamps, and the stump is oversewn with a monolament suture. The variable-sized portal branches of the caudate lobe are carefully divided, and the canal of Arantius is divided at its origin to the left portal elbow. As the vascular inow of the right liver is completely controlled, the right hemiliver and caudate lobe are fully mobilized by dividing the right and short hepatic veins. Liver transection is initiated along the ischemic demarcation (the main portal ssure) using Pringle’s maneuver, advancing along the middle hepatic vein that leaves on the transection surface. When the liver transection is completed, the left hepatic duct is circumferentially exposed. After the clamp is placed on the distal side to minimize bile spillage, the intra-
58 Hepatopancreatoduodenectomy (HPD) forBiliary Tract Cancers
Fig. 58.3 Resected specimen
after hepatopancreatoduode­nectomy. The bile duct was opened longitudinally. Although the tumor was located mainly at the level of the pancreatic entry (arrow head), indicating distal cholangiocarcinoma, the photo visualized a laterally­spreading cholangiocarci­noma (bracket)
Ampulla of Vater
Duodenum
Pancreatic head
Gallbladder
Righthepatic duct
431
Right liver
Proximalductstump
Bile duct
of the caudate lobe
Caudate lobe
Left liver
Caudate
lobe
IVC
Fig. 58.4 Completion photo of pancreatoduodenectomy combined
with hepatectomy. Pancreatoduodenectomy was performed for gall­bladder cancer with extensive nodal involvement, followed by right hepatectomy for hepatocellular carcinoma. The common bile duct was divided and the hilar bile duct remained in situ. This procedure is not categorized as hepatopancreatoduodenectomy. IVC inferior vena cava
Bile duct stump
Pancreas
Stomach
hepatic bile duct is divided with scissors. The stump of the intrahepatic duct is located at the right side of the left portal elbow.
Finally, the pancreatic remnant, intrahepatic bile duct, and stomach are reconstructed with a Roux-en Y jejunal limb in the order listed (modied Child method). We usually perform duct-to-mucosa anastomosis followed by a sero­muscular envelope (Blumgart method) for end-to-side pan­creatojejunostomy, and a single-layer interrupted end-to- side hepaticojejunostomy. Our perioperative management has been previously described [16].
58.1.3 Pioneers ofHPD
In 1976, Kasumi etal. [17] reported a surgical strategy for advanced gallbladder cancer in a Japanese article, in which one of the 11 patients received a right hepatectomy, PD, and bile duct resection. Although the detailed information of this patient was not given, this procedure was the rst successful HPD in Japan. In 1980, Takasaki etal. [18] reported 5 case series of HPD for locally advanced gallbladder cancer in detail. These patients had bulky tumors measuring 3 to 10cm in diameter; direct involvement of the pancreatic head or the duodenum, and extensive nodal metastasis. For curative intent, all patients underwent HPD including extended right hepatectomy, and one patient received combined portal vein resection and reconstruction. Unfortunately, 3 of the 5 patients died within 30days after surgery, signifying a mor­tality rate up to 60%; the remaining 2 patients were alive without disease 5 and 16 months after surgery. Takasaki’s report clearly showed a technical feasibility of HPD; how-
432
T. Ebata et al.
ever, the optimal indication, safety assessment, and survival benet of HPD remained equivocal at that time. Thus, HPD was initiated against far-advanced gallbladder cancer in Japan approximately 40 years ago, and patients, if unre­sected, just had to receive best supportive care, ending in a very short survival time of 4months. Considering these dif­cult backgrounds, HPD would be unsatisfactory but at least better than untreated option. At present, the following over 30years’ history of HPD [1921] says that such patients fail to get a survival benet from HPD.

58.1.4 Outcomes After HPD

Although not many, some specic centers have continued to perform HPD in selected patients. Because portal vein embo­lization has been widely used in the preoperative manage­ment, the incidence of liver failure has decreased gradually in patients undergoing HPD [22]. Accordingly, nearly zero mortality is often reported in high-volume centers [13, 23,
24]. Nonetheless, a few authors have reported a high mortal-
ity, 13% to 21% [2527], indicating a high-risk nature of HPD.
A favorable survival rate was observed in cholangiocar­cinoma. Kaneoka etal. [25] and Miwa etal. [28] demon­strated 5-year survival rates of 52% (n = 9) and 64% (n=10), respectively. In addition, Ebata etal. [16] reported 85 patients with cholangiocarcinoma who underwent HPD between 1992 and 2011; the reported overall survival rate was 37% at 5years. Together, these results show that HPD provides a survival benet in selected patients with cholangiocarcinoma.
As for gallbladder cancer, most studies [2529] consis­tently showed a poor survival. Mizuno et al. [19] recently observed a median survival time of only 10months after HPD in 38 gallbladder cancer patients, which equals to a sur­vival time in patients with unresectable disease who received the rst-line chemotherapy [30]. This nding clearly sug­gests a decreased oncologic value of up-front HPD in gall­bladder cancer. However, they identied that patients with cystic duct cancer may be a potential beneciary [19]. This disease is now categorized in gallbladder tumor, but behaves similar to cholangiocarcinoma due to its anatomical approxi­mation to the common bile duct.

58.1.5 Practical Management During Surgery

HPD is indicated as a treatment for the following modes of spread in cholangiocarcinoma that otherwise can be com­pletely removed: (1) a diffusely inltrating tumor of the whole extrahepatic bile duct; (2) a perihilar tumor exhibiting downward supercial spreading [4, 31], or inversely; (3) a
distal tumor exhibiting upward supercial spreading; (4) a middle tumor inltrating both the right hepatic artery and the pancreatic head at the advancing margin; (5) a perihilar tumor with bulky nodal metastasis of the pancreatoduodenal region; and nally, (6) multiple bile duct tumors. Recently, Toyoda etal. [32] investigated cholangiographic ndings in 100 patients who underwent HPD, and found that patients with localized type (the above 2 and 3 types tumor) had a better survival than those with diffuse type: 59.0% vs 26.3% at 5years.
During hepatobiliary resection, a frozen section histo­logic examination often reveals cancer involvement at the distal ductal stump. Surgical management in this setting is controversial because the biologic aggressiveness of the remnant tumor depends on its histology (i.e., invasive versus non-invasive cancer). Margin involvement with invasive can­cer signicantly reduced rate of survival [4, 33, 34]; there­fore, PD should be performed when the distal ductal margin is involved with invasive cancer, provided that the other sur­gical margins are tumor-free [35]. In contrast, several practi­cal options can be employed for the treatment of a positive distal ductal margin with non-invasive cancer because rem­nant non-invasive foci show a slow progressive nature with a mild survival impact [36]. Therefore, it works as a signicant prognostic indicator in the subset with T1-2N0 disease (early-stage disease); whereas, it does not in the subset with advanced disease or in the whole resected cohort [4, 33, 34]. Considering these ndings, the additional resection of the intrapancreatic duct alone is rst recommended [37]. When the margin is still positive after addition ductal resection, then PD should be considered unless the patient has other adverse prognostic factors representing nodal metastasis, pancreatic invasion, or vascular invasion [3, 5, 16, 38, 39].
Conict of interest
None.

References

1. Sakamoto E, Nimura Y, Hayakawa N, etal. The pattern of inltra-
tion at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–11.
2. Ebata T, Watanabe H, Ajioka Y, Oda K, Nimura Y. Pathological
appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89:1260–7.
3. Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino
M.The concept of perihilar cholangiocarcinoma is valid. Br J Surg. 2009;96:926–34.
4. Igami T, Nagino M, Oda K, etal. Clinicopathologic study of cholan-
giocarcinoma with supercial spread. Ann Surg. 2009;249:296–302.
5. Nagino M, Nimura Y, Nishio H, etal. Hepatectomy with simulta-
neous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg. 2010;252:115–23.
6. Nagino M, Ebata T, Yokoyama Y, etal. Evolution of surgical treat-
ment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 2013;258:129–40.
58 Hepatopancreatoduodenectomy (HPD) forBiliary Tract Cancers
433
7. Miyagawa S, Makuuchi M, Kawasaki S, etal. Outcome of major hepatectomy with pancreatoduodenectomy for advanced biliary malignancies. World J Surg. 1996;20:77–80.
8. Shirai Y, Ohtani T, Tsukada K, Hatakeyama K. Combined pan­creaticoduodenectomy and hepatectomy for patients with locally advanced gallbladder carcinoma: long term results. Cancer. 1997;80:1904–9.
9. D'Angelica M, Martin RC 2nd, Jarnagin WR, Fong Y, DeMatteo RP, Blumgart LH. Major hepatectomy with simultaneous pan­createctomy for advanced hepatobiliary cancer. J Am Coll Surg. 2004;198:570–6.
10. Gleisner AL, Assumpcao L, Cameron JL, etal. Is resection of peri­ampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justied? Cancer. 2007;110:2484–92.
11. McKay A, Sutherland FR, Bathe OF, Dixon E.Morbidity and mor­tality following multivisceral resections in complex hepatic and pancreatic surgery. J Gastrointest Surg. 2008;12:86–90.
12. Hartwig W, Hackert T, Hinz U, etal. Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg. 2009;250:81–7.
13. Hemming AW, Magliocca JF, Fujita S, et al. Combined resec­tion of the liver and pancreas for malignancy. J Am Coll Surg. 2010;210(808–14):14–6.
14. Nakamura S, Nishiyama R, Yokoi Y, et al. Hepatopancreato­duodenectomy for advanced gallbladder carcinoma. Arch Surg. 1994;129:625–9.
15. Sasaki R, Takahashi M, Funato O, et al. Hepatopancreatoduode­nectomy with wide lymph node dissection for locally advanced carcinoma of the gallbladder—long-term results. Hepato-Gastroen­terology. 2002;49:912–5.
16. Ebata T, Yokoyama Y, Igami T, etal. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.
17. Kasumi F, Takagi K, Konishi T, Sakamoto G.Surgical treatment of carcinoma of the gallbladder, analysing its modes of spread (in Japanese). Jpn J Gatroenterol Surg. 1976;9:170–7.
18. Takasaki K, Kobayashi S, Mutoh H, et al. Our experiences (5 cases) of extended right lobectomy combined with pancreato­duodenectomy for the carcinoma of the gall bladder (in Japanese). Tan to Sui. 1980;1:923–32.
19. Mizuno T, Ebata T, Yokoyama Y, etal. Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. Br J Surg. 2019;106:626–35.
20. Higuchi R, Ota T, Araida T, etal. Surgical approaches to advanced gallbladder cancer: a 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol. 2014;21:4308–16.
21. Araida T, Yoshikawa T, Azuma T, Ota T, Takasaki K, Hanyu F. Indications for pancreatoduodenectomy in patients undergoing lymphadenectomy for advanced gallbladder carcinoma. J Hepato­Biliary- Pancreat Surg. 2004;11:45–9.
22. Ebata T, Nagino M, Nishio H, Arai T, Nimura Y.Right hepatopan­creatoduodenectomy: improvements over 23 years to attain accept­ability. J Hepato-Biliary-Pancreat Surg. 2007;14:131–5.
23. Kaneoka Y, Yamaguchi A, Isogai M, Kumada T. Survival benet of hepatopancreatoduodenectomy for cholangiocarcinoma in com-
parison to hepatectomy or pancreatoduodenectomy. World J Surg. 2010;34:2662–70.
24. Aoki T, Sakamoto Y, Kohno Y, etal. Hepatopancreaticoduodenectomy for biliary cancer: strategies for near-zero operative mortality and acceptable long-term outcome. Ann Surg. 2018;267:332–7.
25. Kaneoka Y, Yamaguchi A, Isogai M.Hepatopancreatoduodenectomy: its suitability for bile duct cancer versus gallbladder cancer. J Hepato-Biliary-Pancreat Surg. 2007;14:142–8.
26. Lim CS, Jang JY, Lee SE, Kang MJ, Kim SW.Reappraisal of hepa­topancreatoduodenectomy as a treatment modality for bile duct and gallbladder cancer. J Gastrointest Surg. 2012;16:1012–8.
27. Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg. 2008;32:1067–74.
28. Miwa S, Kobayashi A, Akahane Y, etal. Is major hepatectomy with pancreatoduodenectomy justied for advanced biliary malignancy? J Hepato-Biliary-Pancreat Surg. 2007;14:136–41.
29. Sakamoto Y, Nara S, Kishi Y, etal. Is extended hemihepatectomy plus pancreaticoduodenectomy justied for advanced bile duct can­cer and gallbladder cancer? Surgery. 2013;153:794–800.
30. Valle J, Wasan H, Palmer DH, etal. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
31. Nakamura S, Suzuki S, Serizawa A, etal. Hepatopancreatoduode­nectomy for supercially spreading bile duct carcinoma: a report of two 5 year survivals. Hepato- Gastroenterology. 1996;43:138–42.
32. Toyoda Y, Ebata T, Mizuno T, et al. Cholangiographic tumor classication for simple patient selection prior to hepatopan­creatoduodenectomy for cholangiocarcinoma. Ann Surg Oncol. 2019;26:2971–9.
33. Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K.Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103:1210–6.
34. Shingu Y, Ebata T, Nishio H, Igami T, Shimoyama Y, Nagino M. Clinical value of additional resection of a margin- positive proximal bile duct in hilar cholangiocarcinoma. Surgery. 2010;147:49–56.
35. Otsuka S, Ebata T, Yokoyama Y, etal. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholan­giocarcinoma. Br J Surg. 2019;106:774–82.
36. Tsukahara T, Ebata T, Shimoyama Y, etal. Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas. Ann Surg. 2017;266:126–32.
37. Kondo S, Hirano S, Ambo Y, et al. Pancreas-preserving biliary amputation with pancreatic diversion: a new surgical technique for complete resection of the intrapancreatic biliary system. Hepato­Gastroenterology. 2004;51:1255–8.
38. Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y.Hepatectomy with portal vein resection for hilar cholangiocarci­noma: audit of 52 consecutive cases. Ann Surg. 2003;238:720–7.
39. Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg. 2013;257:718–25.

Hepato-biliary Injuries

EnderDulundu
59
Abstract
Hepatobiliary surgery has become a safer as a result of considerable progress in equipment, technology, periop­erative management, and surgical techniques. However, hepato-biliary surgical complications still remain as a serious problem.
Laparoscopic cholecystectomy is one of the most com­monly performed abdominal surgical procedures through the world, and as a result hepato-biliary injuries are encountered after this procedure. Iatrogenic hepato­biliary injuries occur after various types of procedures such as surgical, interventional, and endoscopic interven­tions, and may needs surgical managements to overcome.
These injuries may be identied during, subsequently after, or in the late after the procedure, and may result in substantial morbidity and mortality. Hepato-biliary inju­ries are categorized into vascular, parenchymal or biliary injuries such as arteriovenous stulas, bleeding, haema­toma, uid collection-abscesses, biliary leak or stricture. These injuries can manifest themselves with some clinical ndings and laboratory results.
Although numerous imaging modalities such as ultra­sound, computed tomography, magnetic resonance imag­ing, and digital subtraction angiography are critical for proper diagnosis and have facilitated management hepato­biliary injuries especially bile duct injury which is usually occur after simple cholecystectomy can be one of the most difcult challenges for the surgeons to overcome.
As new technologies became available (i.e. uores­cence guided surgery), physicians must follow the devel­opments and adapt them to a daily practice to achieve
E. Dulundu (*) Department of General Surgery, HPB Unit, Director of Liver Transplantation Unit, Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey e-mail: ender.dulundu@iuc.edu.tr
more secure results. There are several pathological condi­tions that predispose to hepatobiliary injury (etc.; sclero­atroc gallbladder, Mirrizi’s syndrome, hepatic neoplasm, obesity), surgeon should be aware and take into account of all these conditions preoperatively.
Multidisciplinary treatment strategies and team work especially with interventional radiologists are crucial to the management of these complications.
Hepatobiliary system injuries are an important cause of mor­bidity and mortality that can occur after surgery such as cho­lecystectomy, liver resections, pancreatic surgery, gastrointestinal surgery, and non surgical procedures (i.e. ERCP, PTHC, or percutaneous biopsy) [13].
These injuries can be noticed during surgery, or they can
manifest themselves in the early period following the sur­gery, months or even years later. Frequently they result in additional surgeries, long recovery time, as well as an increase in hospital costs of up to 126% [4, 5].
Hepatobiliary injuries should be evaluated by a multidis-
ciplinary team including hepatobiliary surgeon, gastroenter­ologist, and preferably an experienced interventional radiologist [6].

59.1 Etiology

Cholecystectomy is one of the most common causes of iatro­genic biliary injuries. Incidence of bile duct injury (BDI) is widely reported at 0.4% to 0.6% in laparoscopic cholecys­tectomy, and 0.2–0.3% with open surgery [2, 5, 79].
Traumatic injury to the biliary tree and gallbladder is a
rare occurrence typically seen in the setting of blunt trauma, and injury to the biliary tree is seen in only 0.1% of trauma cases [10]. Especially in hilar tumors following radiofre­quency ablation bile duct injuries can be seen in 0.1% to 12% [11].
© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022 M. Makuuchi et al. (eds.), The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases,
https://doi.org/10.1007/978-981-19-0063-1_59
435